ES2778033T3 - Enzimas específicas de sitio y métodos de uso - Google Patents
Enzimas específicas de sitio y métodos de uso Download PDFInfo
- Publication number
- ES2778033T3 ES2778033T3 ES13854876T ES13854876T ES2778033T3 ES 2778033 T3 ES2778033 T3 ES 2778033T3 ES 13854876 T ES13854876 T ES 13854876T ES 13854876 T ES13854876 T ES 13854876T ES 2778033 T3 ES2778033 T3 ES 2778033T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- nucleic acid
- sequence
- dna
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727652P | 2012-11-16 | 2012-11-16 | |
| US201361802066P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/070636 WO2014078819A2 (en) | 2012-11-16 | 2013-11-18 | Site-specific enzymes and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2778033T3 true ES2778033T3 (es) | 2020-08-07 |
Family
ID=50731839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13854876T Active ES2778033T3 (es) | 2012-11-16 | 2013-11-18 | Enzimas específicas de sitio y métodos de uso |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10415024B2 (de) |
| EP (1) | EP2920319B1 (de) |
| JP (2) | JP6502259B2 (de) |
| CN (1) | CN105051204B (de) |
| AU (3) | AU2013344375B2 (de) |
| CA (1) | CA2891510C (de) |
| ES (1) | ES2778033T3 (de) |
| WO (1) | WO2014078819A2 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2825190T3 (en) * | 2012-03-15 | 2017-02-27 | Cellectis | REPEAT VARIABLE DIRESTS FOR TARGETING NUCLEOTIDES |
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| US12312383B2 (en) | 2018-04-18 | 2025-05-27 | Altius Institute For Biomedical Sciences | Animal pathogen-derived polypeptides and uses thereof for genetic engineering |
| WO2020006132A1 (en) | 2018-06-27 | 2020-01-02 | Altius Institute For Biomedical Sciences | Gapped and tunable repeat units for use in genome editing and gene regulation compositions |
| US12264181B2 (en) | 2018-06-27 | 2025-04-01 | Altius Institute For Biomedical Sciences | Nucleic acid binding domains and methods of use thereof |
| US12209259B2 (en) | 2018-06-27 | 2025-01-28 | Altius Institute For Biomedical Sciences | Nucleases for genome editing |
| CA3124103A1 (en) | 2018-12-20 | 2020-06-25 | Poseida Therapeutics, Inc. | Nanotransposon compositions and methods of use |
| WO2020209332A1 (ja) * | 2019-04-09 | 2020-10-15 | 国立研究開発法人科学技術振興機構 | 核酸結合性タンパク質 |
| US20220372105A1 (en) | 2019-09-05 | 2022-11-24 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
| CN113355345B (zh) * | 2020-03-06 | 2023-05-23 | 深圳蓝晶生物科技有限公司 | 一种基因组整合外源序列的方法 |
| WO2021183795A1 (en) | 2020-03-11 | 2021-09-16 | Poseida Therapeutics, Inc. | Chimeric stimulatory receptors and methods of use in t cell activation and differentiation |
| US20240000969A1 (en) | 2020-10-21 | 2024-01-04 | Poseida Therapeutics San Diego | Compositions and methods for delivery of nucleic acids |
| EP4298205A1 (de) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Genetisch modifizierte induzierte pluripotente stammzellen und verfahren zur verwendung davon |
| EP4297728A1 (de) | 2021-02-23 | 2024-01-03 | Poseida Therapeutics, Inc. | Zusammensetzungen und verfahren zur abgabe von nukleinsäuren |
| WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
| EP4413141A1 (de) | 2021-10-04 | 2024-08-14 | Poseida Therapeutics, Inc. | Transposonzusammensetzungen und verfahren zur verwendung davon |
| US20250099383A1 (en) | 2022-01-21 | 2025-03-27 | Poseida Therapeutics, Inc. | Compositions and methods for delivery of nucleic acids |
| EP4482967A1 (de) | 2022-02-23 | 2025-01-01 | Poseida Therapeutics, Inc. | Genetisch modifizierte zellen und verfahren zur verwendung davon |
| JP2025539816A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法 |
| JP2025539712A (ja) | 2022-11-21 | 2025-12-09 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 遺伝子編集されたｔ細胞の増殖能を評価するための方法 |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| KR20250162510A (ko) | 2023-01-20 | 2025-11-18 | 포세이다 테라퓨틱스, 인크. | 리피도이드 화합물 및 관련 조성물 및 용도 |
| WO2024155931A1 (en) | 2023-01-20 | 2024-07-25 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| KR20250166122A (ko) | 2023-02-21 | 2025-11-27 | 포세이다 테라퓨틱스, 인크. | 게놈 편집을 위한 조성물 및 방법 |
| EP4669746A1 (de) | 2023-02-21 | 2025-12-31 | Poseida Therapeutics, Inc. | Zusammensetzungen und verfahren zur genomeditierung |
| CN121335979A (zh) | 2023-05-17 | 2026-01-13 | 波西达治疗公司 | 靶向hbg1和hbg2的组合物及其使用方法 |
| WO2025049925A2 (en) | 2023-09-01 | 2025-03-06 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025096980A1 (en) | 2023-11-02 | 2025-05-08 | Poseida Therapeutics, Inc. | Compositions targeting klkb1 and methods of use thereof |
| WO2025160432A1 (en) | 2024-01-26 | 2025-07-31 | Poseida Therapeutics, Inc. | Methods and compositions for enhancing in vivo persistence and potency of cell therapy |
| WO2025171237A1 (en) | 2024-02-08 | 2025-08-14 | Poseida Therapeutics, Inc. | Lipidoid compounds and related compositions and uses |
| WO2025221789A1 (en) | 2024-04-16 | 2025-10-23 | Poseida Therapeutics, Inc. | Compositions and methods for use in car/tcr cell therapies |
| WO2026080393A1 (en) | 2024-10-07 | 2026-04-16 | Poseida Therapeutics, Inc. | Compositions and methods for use in car cell therapies |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5672344A (en) | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5529774A (en) | 1991-08-13 | 1996-06-25 | The Regents Of The University Of California | In vivo transfer of the HSV-TK gene implanted retroviral producer cells |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| TW261517B (de) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5911983A (en) | 1992-06-26 | 1999-06-15 | University Of Pittsburgh | Gene therapy for Gaucher disease using retroviral vectors |
| JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
| US5645829A (en) | 1993-06-18 | 1997-07-08 | Beth Israel Hospital Association | Mesothelial cell gene therapy |
| US5656465A (en) | 1994-05-04 | 1997-08-12 | Therion Biologics Corporation | Methods of in vivo gene delivery |
| US5714353A (en) | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| US5639642A (en) | 1994-06-16 | 1997-06-17 | Novo Nordisk A/S | Synthetic leader peptide sequences |
| US7285416B2 (en) | 2000-01-24 | 2007-10-23 | Gendaq Limited | Regulated gene expression in plants |
| DE19524720A1 (de) | 1995-07-12 | 1997-01-16 | Hoechst Ag | Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinasn-3" |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| JP4216350B2 (ja) | 1994-09-19 | 2009-01-28 | 大日本住友製薬株式会社 | 動物細胞感染用の組換えｄｎａウイルスベクター |
| US5789147A (en) | 1994-12-05 | 1998-08-04 | New York Blood Center, Inc. | Method for concentrating white cells from whole blood by adding a red cell sedimentation reagent to whole anticoagulated blood |
| US5869040A (en) | 1995-06-07 | 1999-02-09 | Biogen, Inc | Gene therapy methods and compositions |
| US5928914A (en) | 1996-06-14 | 1999-07-27 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Methods and compositions for transforming cells |
| WO2000002996A2 (en) | 1998-07-10 | 2000-01-20 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type iii secretion systems |
| CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| AU6045900A (en) | 1999-05-25 | 2000-12-12 | Panorama Research, Inc. | Interaction-activated proteins |
| ATE353361T1 (de) | 2000-04-28 | 2007-02-15 | Sangamo Biosciences Inc | Gezielten modifikation der chromatinstruktur |
| WO2002057293A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
| US20030138850A1 (en) | 2001-10-18 | 2003-07-24 | Ekkehard Mossner | Selecting for antibody-antigen interactions in bacteria cells by employing a protein fragment complementation assay |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| US8021849B2 (en) | 2004-11-05 | 2011-09-20 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the determination of sirolimus in a sample |
| US20060252140A1 (en) | 2005-04-29 | 2006-11-09 | Yant Stephen R | Development of a transposon system for site-specific DNA integration in mammalian cells |
| US7790379B2 (en) | 2005-05-19 | 2010-09-07 | Universite De Geneve | Mapping of proteins along chromatin by chromatin cleavage |
| WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
| JP2007159512A (ja) | 2005-12-15 | 2007-06-28 | Institute Of Physical & Chemical Research | Ｉｉｓ型制限酵素を用いる翻訳終止コドンの除去方法 |
| US20100015661A1 (en) | 2006-04-21 | 2010-01-21 | Mab-Factory Gmbh | Antibody-rnase-conjugate |
| EP2155868A2 (de) | 2007-04-19 | 2010-02-24 | Codon Devices, Inc | Gentechnisch hergestellte nukleasen und deren verwendungen beim nukleinsäurezusammenbau |
| JP2010538659A (ja) | 2007-09-17 | 2010-12-16 | アフォミックス コーポレイション | デュアルベイトレポーターを用いてｓｃＦｖスクリーニングにおける特異性を増大させる方法 |
| CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| WO2010147686A2 (en) | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| KR101556359B1 (ko) | 2011-01-03 | 2015-10-01 | 주식회사 툴젠 | 디자인된 tal 이펙터 뉴클레아제를 통한 게놈 엔지니어링 |
| WO2012092970A1 (en) | 2011-01-06 | 2012-07-12 | Complix Nv | Alphabody libraries and methods for producing the same |
| US9499592B2 (en) * | 2011-01-26 | 2016-11-22 | President And Fellows Of Harvard College | Transcription activator-like effectors |
| CA3111953C (en) | 2011-04-05 | 2023-10-24 | Cellectis | Method for the generation of compact tale-nucleases and uses thereof |
| EP2522726A1 (de) | 2011-05-12 | 2012-11-14 | Fundació Privada Centre de Regulació Genòmica (CRG) | Zinkfingernukleasen für p53-Änderung |
| US20140201858A1 (en) | 2011-05-17 | 2014-07-17 | Transposagen Biopharmaceuticals, Inc | Methods for site-specific genetic modification in stem cells using xanthomonas tal nucleases (xtn) for the creation of model organisms |
| US9410134B2 (en) | 2011-06-07 | 2016-08-09 | Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt | Protein having nuclease activity, fusion proteins and uses thereof |
| WO2012168307A2 (en) | 2011-06-07 | 2012-12-13 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Improved recombination efficiency by inhibition of nhej dna repair |
| UA115772C2 (uk) | 2011-12-16 | 2017-12-26 | Таргітджин Байотекнолоджиз Лтд | Композиція програмованого нуклеопротеїнового молекулярного комплексу і спосіб модифікування заданої послідовності нуклеїнової кислоти-мішені |
| WO2013152220A2 (en) | 2012-04-04 | 2013-10-10 | Life Technologies Corporation | Tal-effector assembly platform, customized services, kits and assays |
| WO2013177231A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US9181535B2 (en) | 2012-09-24 | 2015-11-10 | The Chinese University Of Hong Kong | Transcription activator-like effector nucleases (TALENs) |
| AU2013336601B2 (en) | 2012-10-26 | 2018-01-25 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
| CA2891510C (en) | 2012-11-16 | 2022-10-18 | Transposagen Biopharmaceuticals, Inc. | Site-specific enzymes and methods of use |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| WO2014093655A2 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| EP3115457B1 (de) | 2014-03-05 | 2019-10-02 | National University Corporation Kobe University | Genomsequenzmodifizierungsverfahren zur spezifischen umwandlung von nukleinsäurebasen einer gezielten dna-sequenz und molekularkomplex zur verwendung darin |
| US20170107541A1 (en) | 2014-06-17 | 2017-04-20 | Poseida Therapeutics, Inc. | A method for directing proteins to specific loci in the genome and uses thereof |
| CA2952618A1 (en) | 2014-06-17 | 2015-12-23 | Poseida Therapeutics, Inc. | Methods and compositions for in vivo non-covalent linking |
| US11473082B2 (en) | 2015-06-17 | 2022-10-18 | Poseida Therapeutics, Inc. | Compositions and methods for directing proteins to specific loci in the genome |
-
2013
- 2013-11-18 CA CA2891510A patent/CA2891510C/en active Active
- 2013-11-18 US US14/443,361 patent/US10415024B2/en active Active
- 2013-11-18 AU AU2013344375A patent/AU2013344375B2/en active Active
- 2013-11-18 WO PCT/US2013/070636 patent/WO2014078819A2/en not_active Ceased
- 2013-11-18 JP JP2015543101A patent/JP6502259B2/ja active Active
- 2013-11-18 EP EP13854876.3A patent/EP2920319B1/de active Active
- 2013-11-18 ES ES13854876T patent/ES2778033T3/es active Active
- 2013-11-18 CN CN201380066881.0A patent/CN105051204B/zh active Active
-
2017
- 2017-08-30 AU AU2017221779A patent/AU2017221779B2/en active Active
-
2018
- 2018-03-27 JP JP2018060486A patent/JP2018099136A/ja not_active Withdrawn
-
2019
- 2019-07-22 US US16/518,126 patent/US10844361B2/en active Active
- 2019-08-16 AU AU2019216699A patent/AU2019216699B2/en active Active
-
2020
- 2020-11-16 US US17/098,974 patent/US20210062170A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2891510C (en) | 2022-10-18 |
| WO2014078819A2 (en) | 2014-05-22 |
| EP2920319A4 (de) | 2016-07-06 |
| AU2017221779A1 (en) | 2017-09-28 |
| JP2015535010A (ja) | 2015-12-07 |
| CA2891510A1 (en) | 2014-05-22 |
| AU2019216699A1 (en) | 2019-09-19 |
| AU2013344375A1 (en) | 2015-06-11 |
| AU2017221779B2 (en) | 2019-05-16 |
| JP2018099136A (ja) | 2018-06-28 |
| BR112015010911A2 (pt) | 2022-10-25 |
| AU2019216699B2 (en) | 2021-03-04 |
| US20160060610A1 (en) | 2016-03-03 |
| HK1215284A1 (en) | 2016-08-19 |
| US20210062170A1 (en) | 2021-03-04 |
| EP2920319A2 (de) | 2015-09-23 |
| US10415024B2 (en) | 2019-09-17 |
| US10844361B2 (en) | 2020-11-24 |
| CN105051204B (zh) | 2023-07-21 |
| EP2920319B1 (de) | 2020-02-19 |
| JP6502259B2 (ja) | 2019-04-17 |
| AU2013344375B2 (en) | 2017-09-14 |
| US20200199553A1 (en) | 2020-06-25 |
| CN105051204A (zh) | 2015-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2778033T3 (es) | Enzimas específicas de sitio y métodos de uso | |
| JP7170090B2 (ja) | タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法 | |
| CN109153999B (zh) | 原位重组产生的核酸酸链 | |
| US20080209587A1 (en) | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination | |
| WO2019126578A1 (en) | Compositions and methods for directing proteins to specific loci in the genome | |
| BR112015010911B1 (pt) | Enzimas específicas de sítio e métodos de uso | |
| HK1215284B (en) | Site-specific enzymes and methods of use | |
| HK40065962A (en) | Compositions and methods for directing proteins to specific loci in the genome | |
| AU2007201617B2 (en) | Methods and Compositions for using Zinc Finger Endonucleases to Enhance Homologous Recombination | |
| CN121975771A (en) | Compositions and methods for targeting proteins to specific loci in the genome | |
| HK1253508B (en) | Compositions and methods for directing proteins to specific loci in the genome | |
| HK40002290B (en) | Recombinogenic nucleic acid strands in situ | |
| HK40002290A (en) | Recombinogenic nucleic acid strands in situ | |
| HK1073331B (en) | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination | |
| HK1073331C (en) | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |